IMNM SEC Filing News — Immunome, Inc.

Latest SEC filings for Immunome, Inc. (IMNM) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-05.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It …
Sector: Healthcare Industry: Biotechnology Market Cap: $2.0B CIK: 1472012
20
Total Filings
0
Bullish Classifications
6
Bearish Classifications
13
Insider Transactions
2
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for IMNM currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
IMNM Filing Activity Snapshot 2026-07-07 — 2026-10-05
Insider Transactions (Form 4)
0 buys vs 6 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$2.77M
ABHMC II, LLC · 2026-08-06
108,504 shares · Form 144
Form 144 Notices
4
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Immunome, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 7 compensation award and 6 open-market sale. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×6
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-09-15

IMNM insider Higgins Jack (Chief Scientific Officer) sold 13,200 shares (~$334.2K)

Higgins Jack, listed as Chief Scientific Officer at Immunome Inc., reported an open-market sale of 13,200 IMNM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 18,000 $1.35 $24.3K
S Open-market sale 13,200 $25.32 $334.2K
G Gift 8,800 — —
M Option exercise derivative · Employee Stock Option (right to buy) 18,000 — —
Filing: Form 4 (Insider Transaction) Insider: Higgins Jack (Chief Scientific Officer) Shares: 13,200 Est. Value: $334.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

IMNM insider Barchas Isaac (Director) sold 83,464 shares (~$2.20M)

Barchas Isaac, listed as Director at Immunome Inc., reported an open-market sale of 83,464 IMNM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 10,125 $26.07 $264.0K
S Open-market sale 62,291 $26.23 $1.63M
S Open-market sale 11,048 $27.25 $301.1K
Filing: Form 4 (Insider Transaction) Insider: Barchas Isaac (Director) Shares: 83,464 Est. Value: $2.20M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-10

IMNM insider Barchas Isaac (Director) sold 36,088 shares (~$940.5K)

Barchas Isaac, listed as Director at Immunome Inc., reported an open-market sale of 36,088 IMNM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 20,840 $26.06 $543.1K
S Open-market sale 15,248 $26.06 $397.4K
Filing: Form 4 (Insider Transaction) Insider: Barchas Isaac (Director) Shares: 36,088 Est. Value: $940.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-06

IMNM insider Horn Kinney (CHIEF BUSINESS OFFICER) sold 90,616 shares (~$2.27M)

Horn Kinney, listed as CHIEF BUSINESS OFFICER at Immunome Inc., reported an open-market sale of 90,616 IMNM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 50,366 $12.92 $650.7K
M Option exercise 40,250 $10.60 $426.6K
S Open-market sale 90,616 $25.09 $2.27M
M Option exercise derivative · Employee Stock Option (right to buy) 50,366 — —
M Option exercise derivative · Employee Stock Option (right to buy) 40,250 — —
Filing: Form 4 (Insider Transaction) Insider: Horn Kinney (CHIEF BUSINESS OFFICER) Shares: 90,616 Est. Value: $2.27M
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

Horn Kinney (CHIEF BUSINESS OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 31,250 — —
A Compensation award derivative · Employee Stock Option (right to buy) 62,500 — —
Filing: Form 4 (Insider Transaction) Insider: Horn Kinney (CHIEF BUSINESS OFFICER) Shares: 31,250
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

Tsai Philip (Chief Technical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 38,250 — —
A Compensation award derivative · Employee Stock Option (right to buy) 76,500 — —
Filing: Form 4 (Insider Transaction) Insider: Tsai Philip (Chief Technical Officer) Shares: 38,250
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

Stoneman Sandra G. (CHIEF LEGAL OFFICER & GC) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 38,250 — —
A Compensation award derivative · Employee Stock Option (right to buy) 76,500 — —
Filing: Form 4 (Insider Transaction) Insider: Stoneman Sandra G. (CHIEF LEGAL OFFICER & GC) Shares: 38,250
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

Higgins Jack (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 38,250 — —
A Compensation award derivative · Employee Stock Option (right to buy) 76,500 — —
Filing: Form 4 (Insider Transaction) Insider: Higgins Jack (Chief Scientific Officer) Shares: 38,250
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

Rosett Max (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 47,250 — —
A Compensation award derivative · Employee Stock Option (right to buy) 94,500 — —
Filing: Form 4 (Insider Transaction) Insider: Rosett Max (Chief Financial Officer) Shares: 47,250
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

Lechleider Robert (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 54,000 — —
A Compensation award derivative · Employee Stock Option (right to buy) 108,000 — —
Filing: Form 4 (Insider Transaction) Insider: Lechleider Robert (Chief Medical Officer) Shares: 54,000
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-27

IMNM insider Form 4 filed for equity award, exercise, or tax withholding

SIEGALL CLAY B (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 180,000 — —
A Compensation award derivative · Employee Stock Option (right to buy) 360,000 — —
Filing: Form 4 (Insider Transaction) Insider: SIEGALL CLAY B (Director, President and CEO) Shares: 180,000
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-09

IMNM insider Horn Kinney (CHIEF BUSINESS OFFICER) sold 1,092 shares (~$27.3K)

Horn Kinney, listed as CHIEF BUSINESS OFFICER at Immunome Inc., reported an open-market sale of 1,092 IMNM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,092 $12.92 $14.1K
S Open-market sale 1,092 $25.00 $27.3K
M Option exercise derivative · Employee Stock Option (right to buy) 1,092 — —
Filing: Form 4 (Insider Transaction) Insider: Horn Kinney (CHIEF BUSINESS OFFICER) Shares: 1,092 Est. Value: $27.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-07

IMNM insider Barchas Isaac (Director) sold 100,000 shares (~$2.41M)

Barchas Isaac, listed as Director at Immunome Inc., reported an open-market sale of 100,000 IMNM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 83,094 $24.11 $2.00M
S Open-market sale 16,906 $24.20 $409.1K
Filing: Form 4 (Insider Transaction) Insider: Barchas Isaac (Director) Shares: 100,000 Est. Value: $2.41M
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Immunome, Inc. has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-11

IMNM Form 144 filed for proposed insider sale by Higgins Jack (13,200 shares) ~$334.2K

Higgins Jack filed a Form 144 with the SEC indicating intent to sell IMNM (Immunome Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Higgins Jack Shares: 13,200 Est. Value: $334.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-12

IMNM Form 144 filed for proposed insider sale by Barchas Isaac (11,048 shares) ~$301.1K

Barchas Isaac filed a Form 144 with the SEC indicating intent to sell IMNM (Immunome Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Barchas Isaac Shares: 11,048 Est. Value: $301.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-06

IMNM Form 144 filed for proposed insider sale by ABHMC II, LLC (108,504 shares) ~$2.77M

ABHMC II, LLC filed a Form 144 with the SEC indicating intent to sell IMNM (Immunome Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ABHMC II, LLC Shares: 108,504 Est. Value: $2.77M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-04

IMNM Form 144 filed for proposed insider sale by Horn Kinney (90,616 shares) ~$2.27M

Horn Kinney filed a Form 144 with the SEC indicating intent to sell IMNM (Immunome Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Horn Kinney Shares: 90,616 Est. Value: $2.27M
View on SEC EDGAR → Open Filing Document →
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Immunome, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-05

IMNM filed 8-K — material company event

Immunome Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-11

IMNM filed 8-K — material company event

Immunome Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Immunome, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-11

IMNM filed Quarterly Report (10-Q)

Immunome Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Immunome, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on IMNM. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — IMNM SEC Filings

More Tools for IMNM

IMNM Full Stock Analysis IMNM Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper IMNM analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the IMNM stock analysis page.

IMNM Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer